Kestra Medical Technologies (NASDAQ:KMTS) Director Sells 3,908 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Mary Kay Ladone sold 3,908 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total value of $98,481.60. Following the completion of the transaction, the director owned 37,507 shares of the company’s stock, valued at approximately $945,176.40. This represents a 9.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

Shares of Kestra Medical Technologies stock traded down $0.50 on Thursday, hitting $23.57. The company’s stock had a trading volume of 310,496 shares, compared to its average volume of 240,413. The company has a market capitalization of $1.38 billion, a P/E ratio of -9.74 and a beta of 0.62. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $30.00. The firm has a fifty day moving average price of $25.42 and a 200-day moving average price of $22.71. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. On average, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research restated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Finally, JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.14.

Institutional Trading of Kestra Medical Technologies

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the period. Brown Brothers Harriman & Co. raised its holdings in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after purchasing an additional 874 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of Kestra Medical Technologies by 34.6% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after purchasing an additional 1,392 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the period.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.